Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 1,694 trials

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Pulmonary Sarcoidosis: XTMAB-16 Treatment Study

We are testing a new treatment called XTMAB-16 for people with pulmonary sarcoidosis to see if it can safely reduce the need for corticosteroids. This study will help determine the best dose and assess its effectiveness.

Pulmonary Sarcoidosis3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicinePulmonology

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatology

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visitsStandard MedicinesNeurologyPsychiatry

Mantle-Cell Lymphoma: KTE-X19 CAR-T Cell Therapy

We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyInternal Medicine

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Filgotinib for Rare Immune Diseases

We are studying how filgotinib may improve quality of life and disease activity in patients with rare conditions like Behçet's disease, idiopathic inflammatory myopathy, and IgG4-related disease.

DermatomyositisAntisynthetase SyndromeIgG4-Related Disease6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Clostridioides difficile Infection: VE303 Treatment Study

We are testing a new treatment, VE303, to see if it helps prevent recurrent Clostridioides difficile infections in people who have had this infection before. The study will also evaluate safety and quality of life for participants.

Clostridioides difficile Infection6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInfectious Diseases

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Rheumatoid Arthritis: LY3871801 Study

We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyInternal Medicine

Early Breast Cancer: Ribociclib with Endocrine Therapy

We are studying the effects of ribociclib combined with endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. This trial aims to understand how well this treatment works and its safety.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Heart Failure Treatment: Carvedilol vs. Metoprolol

We are comparing two heart medications to see which one may better help patients with heart failure and reduced ejection fraction. This study involves patients who need beta-blocker treatment for their condition.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine